Gynecologic Oncology Clinical Research Group
The research activities of the Gynecologic Oncology Group of Oncology 2 Unit is focused on the treatment of patients with tumor of ovarian, fallopian tube, and primary peritoneal cancers, endometrial and cervical cancers. Through the development and the participation to innovative clinical and translational studies, it aims to improve knowledge of the biology of these disease as well as patients’ outcome and quality of life.
The results of these activities have contributed to some of the most relevant progress in the treatment of these tumors in the last years, presented in the main national and international conferences and published in peer-reviewed scientific journals.
The Group is member of Associazione Italiana Oncologia Medica – AIOM, European Society of Medical Oncology – ESMO, American Association of Clinical Oncology – ASCO, European Society of Gynaecological Oncology – ESGO.
The Group collaborates with the research initiatives of MaNGO (Mario Negri Gynecologic Oncology group) and MITO (Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies).
Multidisciplinary approach to the disease
The management of gynecological cancer is complex and involves multiple specializations. Every case is discussed in a multidisciplinary session in the light of the most up-to date scientific evidence. The objective is to conduce the patient through the complex and challenging diagnostic and therapeutic path, offering the best options for her case all along her disease history.
Immunotherapy is the new frontier
Immunotherapy is one of the most important achievement in last years against cancer. However, there are still many challenges that must be overcome; in particular, in gynecolagical cancer many drugs are still in phase of development.
Treatment with anti-PD1 and antiPD-L1 antibodies represents a large field of research in our center, for example in endometrial and cervical cancer with microsatellite instability (MSI-H), which seem to be particularly sensitive to this kind of therapy.
Combination treatment with immunotherapeutic agents and target therapies such as PARP-inhibitor are under investigation also in ovarian cancer.
Real word evidence studies
To explore the outcome of gynecological tumors in real world practice and to investigate molecular and clinical characteristics impacting on it, we are running observational, large, disease-specific studies on ovarian cancers. These analyses will give the opportunity to improve clinical practice and to generate hypotesis for new clinical researches. Moreover these kind of research allows to better understand the long term effects of our treatments, both on the side of efficacy and of their possible toxicity.
- Prof. Pierfranco Conte, MD, PhD (Coordinator)
- Dr. Giulia Tasca, MD
- Dr. Alice Menichetti, MD
- Dr. Simona Frezzini, MD
- Dr. Giulia Doria
- Ms Daniela Grosso, RNs’ coordinator
- Ms Giulia Pauletti, RN
- Ms Ilenia Gazzetta, RN
- Ms Annalisa Tocco, RN
Internal Collaborations at IOV-IRCCS
- Unit of Surgical Oncology of the Esophagus and Digestive Tract
- Radiotherapy Unit
- Radiology Unit
- Immunology and Molecular Oncology Unit
- Obstretic and Gynecological Clinic, Department of Women and Child’s Health Azienda Ospedale – University of Padua
- Clinica Chirurgica 1, Department of Surgery Oncology and Gastroenterology (DiSCOG), Azienda Ospedale – University of Padua.
- Pathology Service, Department of Medicine, Azienda Ospedale – University of Padua
International and National Collaborations
- Istituto Europeo di Oncologia (IEO) – MIlano
- MaNGO (Mario Negri Gynecologic Oncology group)
- MITO (Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies)
- ENGOT (European Network for Gynaecological Oncological Trial groups)
- ASTRO (Association for translational research in oncology)
- Fondazione Periplo Onlus